Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
Brief Summary: The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America.

Primary Objective:

To assess the efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6, and 12 months in preventing symptomatic virologically-confirmed dengue (VCD) cases, regardless of the severity, due to any of the four serotypes in children and adolescents aged 9 to 16 years at the time of inclusion.

Secondary Objectives:

* To describe the efficacy of CYD dengue vaccine in preventing symptomatic VCD cases after the third dose to the end of the Active Phase, after at least 1 dose, and after 2 doses.
* To describe the occurrence of hospitalized VCD cases and the occurrence of severe (clinically severe or as per World Health Organization (WHO) criteria) VCD cases, throughout the Surveillance Expansion Period (SEP) and throughout the trial (from Day 0 until the end of the study).
* To describe the antibody response to each dengue serotype after Dose 2, after Dose 3, and 1 and 5 years after Dose 3.
* To describe the occurrence of serious adverse events (SAEs), including SAEs of special interest in all participants throughout the trial period.


Options:
A: Arm Label: CYD Dengue Vaccine Group; Type: EXPERIMENTAL; Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: (NaCl) 0.9% solution | Intervention Type: BIOLOGICAL; Name: Live, attenuated, dengue serotype 1, 2, 3, 4 virus; Assigned to Arm(s): CYD Dengue Vaccine Group | Intervention Type: BIOLOGICAL; Name: Placebo: (NaCl) 0.9% solution; Assigned to Arm(s): Placebo Group
B: Arm Label: CYD Dengue Vaccine Group; Type: EXPERIMENTAL; Interventions: Biological: CYD Dengue Vaccine | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Inactivated rabies virus vaccine, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: CYD Dengue Vaccine; Assigned to Arm(s): CYD Dengue Vaccine Group | Intervention Type: BIOLOGICAL; Name: Inactivated rabies virus vaccine; Assigned to Arm(s): Control Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: Dengue Vaccine Group; Type: EXPERIMENTAL; Interventions: Biological: Live, attenuated, dengue serotype 1, 2, 3, 4 virus | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: Sodium chloride (NaCl) 0.9% | Intervention Type: BIOLOGICAL; Name: Live, attenuated, dengue serotype 1, 2, 3, 4 virus; Assigned to Arm(s): Dengue Vaccine Group | Intervention Type: BIOLOGICAL; Name: Placebo: Sodium chloride (NaCl) 0.9%; Assigned to Arm(s): Control Group
D: Arm Label: Intervention clusters; Type: EXPERIMENTAL; Interventions: Biological: Biological (Male Wolbachia-infected Aedes aegypti) | Arm Label: Non-intervention clusters; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Biological (Male Wolbachia-infected Aedes aegypti); Assigned to Arm(s): Intervention clusters

Answer: A